Roche Holding AG (SWX:RO)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 278.18B |
| Revenue (ttm) | 63.49B |
| Net Income (ttm) | 9.43B |
| Shares Out | n/a |
| EPS (ttm) | 11.74 |
| PE Ratio | 29.50 |
| Forward PE | 17.12 |
| Dividend | 9.70 (2.97%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 77,487 |
| Average Volume | 33,258 |
| Open | 332.00 |
| Previous Close | 330.00 |
| Day's Range | 329.60 - 334.80 |
| 52-Week Range | 244.00 - 335.60 |
| Beta | 0.17 |
| RSI | 66.55 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Genentech Announces Agreement With U.S. Government
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced an agreement with the U.S. government that lowers costs for state Medicaid ...
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal
Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the Trump administration towards that goal following a report they are close to a...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Novartis, Roche near US drug price deal, Bloomberg News reports
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as soon as Friday, Bloomberg News reported on Wednesday citing people familiar w...
Roche in pact with Caris to discover cancer drug targets
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
The new cobas® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems. Laborato...
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease
On Wednesday, Roche Holdings AG (OTC: RHHBY) shared data from the phase 3 lidERA Breast Cancer study. The study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-p...
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has obtained CE Mark approval for its mass spectrometry reagent pack designed for antibiotics drug monitoring. This milestone establishes Roc...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu
Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establish...
Questex's Patients as Partners® in Clinical Research Unveils Conference Program, Thought Leaders from Lurie Children's Hospital, Roche Canada and Tufts University School of Medicine to Keynote
Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National Event Takes Place in...
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock
Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company.
Roche boosts Olema after additional late-stage trial data for breast cancer drug
Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluatin...
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advan...
Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Basel, 10 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrin...
Roche Announces CE Mark For Its Cobas BV/CV Assay
(RTTNews) - Roche (RHHBY, RO.SW) announced the CE Mark for its cobas BV/CV assay to identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collecte...
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and ...
European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) f...